Torrent's India sales grew 43% in Q4, beating the US for the first time
The domestic business outpaced the international segment, a shift that reshapes where the pharmaceutical giant's earnings come from.
— 4 earlier stories on Torrent Pharmaceuticals Ltd. →What's new
- India revenue grew 43% in Q4, outpacing the 31% increase in the US business.
- Full-year group revenue climbed 21% to ₹13,980 crore, with Brazil and Germany contributing.
- The presentation provides final audited numbers with detailed segmental performance.
Why this matters
A 43% domestic jump is the headline. India is now growing faster than the US, which for years was the primary driver. That shift lowers exposure to volatile US generics pricing and reshapes the earnings mix.
What we're watching
- Whether India's 43% growth is from new launches or share gains.
- If the US business can sustain a 31% pace beyond the current product cycle.
- The margin profile of the fast-growing India business versus the overall group.
The full read
Torrent finished its financial year on a surge. Q4 group revenue hit ₹4,197 crore, up 42% year-on-year. India led. The domestic business grew 43%, outpacing the US increase of 31%. For the full year, total revenue reached ₹13,980 crore, a 21% gain, with Brazil and Germany contributing as well. The results were flagged earlier by the board. The presentation largely crystallizes final numbers. The key data point is the domestic outperformance. India is now growing faster than the international segments. That changes where Torrent's earnings come from.
Questions answered
- What was the main driver of the 42% Q4 revenue surge?
- The India business led with 43% growth. The US contributed a 31% increase, while Brazil and Germany also grew at strong double-digit rates.
- How did Q4 growth compare to the full year?
- Q4 growth of 42% was a sharp acceleration over the full-year rate of 21%. It indicates the company's performance picked up significantly in the final quarter of FY26.
- Is this new information for the market?
- The top-line trajectory was flagged earlier by the board. The presentation crystallizes final, audited numbers with segmental detail, but the key figures were largely anticipated.
- What does the India vs. US growth differential signal?
- India's 43% growth now outpaces the US increase of 31%. This domestic outperformance changes the growth profile and reduces dependency on US generic cycles.
Torrent Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on TORNTPHARM →- 22 May 2026 · 4:53 PM IST Torrent's India sales grew 43% in Q4, beating the US for the first time
- 40d ago Torrent Pharmaceuticals files transcript for May earnings call
- 45d ago Torrent Pharma walks back US growth targets to single digits
- 45d ago Torrent Pharmaceuticals FY26 results confirm revenue growth of 21%
- 45d ago Torrent Pharmaceuticals eyes ₹5,000 cr QIP following JB Pharma buy